[Stereotactic body radiation therapy for oligometastatic prostate cancer].
CONCLUSION: Treating patients with up to five prostate cancer metastases is efficient and has a low toxicity. Prospective trials should identify which patients, if any, really benefit from this approach. PMID: 29191358 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 27, 2017 Category: Cancer & Oncology Authors: Bibault JE Tags: Bull Cancer Source Type: research

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
azarbachi A Abstract Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory disease or with persistent molecular or radiological (PET-CT scan) residual disease. Within the frame of the 7th annual workshops of the francophone society for bone marrow transplantation and cellular therapy, the working group reviewed the literature in order to elaborate ...
Source: Bulletin du Cancer - November 24, 2017 Category: Cancer & Oncology Authors: Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É, Dumesnil C, Guillaume T, Huynh A, Levrat SM, Menard AL, Michallet M, Pautas C, Poiré X, Ravinet A, Yakoub-Agha I, Bazarbachi A Tags: Bull Cancer Source Type: research

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the French-speaking Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
non C Abstract CAR T-cells are autologous or allogeneic human lymphocytes that are genetically engineered to express a chimeric antigen receptor targeting an antigen expressed on tumor cells such as CD19. CAR T-cells represent a new class of medicinal products, and belong to the broad category of Advanced Therapy Medicinal Products (ATMPs), as defined by EC Regulation 2007-1394. Specifically, they are categorized as gene therapy medicinal products. Although CAR T-cells are cellular therapies, the organization for manufacturing and delivery is far different from the one used to deliver hematopoietic cell grafts, fo...
Source: Bulletin du Cancer - November 23, 2017 Category: Cancer & Oncology Authors: Yakoub-Agha I, Ferrand C, Chalandon Y, Ballot C, Castilla Llorente C, Deschamps M, Gauthier J, Labalette M, Larghero J, Maheux C, Moreau AS, Varlet P, Pétillon MO, Pinturaud M, Rubio MT, Chabannon C Tags: Bull Cancer Source Type: research

[Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)].
The objective of our workshop is to discuss chronic graft versus host disease and to provide recommendations for the indications and treatment of this condition. PMID: 29174321 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 23, 2017 Category: Cancer & Oncology Authors: Magro L, Forcade E, Giraud C, Granata A, Parquet N, Rohrlich PS, Terriou L, Yakoub-Agha I, Beguin Y Tags: Bull Cancer Source Type: research

[European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer].
; E Abstract Endometrial cancer (EC) is a major source of morbidity and mortality in women worldwide. In France, in 2015, EC was the first gynecological cancer in terms of incidence. Its prognosis is considered favorable because it is most often limited to the uterus at diagnosis. Nevertheless, it is a heterogeneous pathology and 5-year overall survival can vary from 92 % to 42 % in FIGO stage I depending on its histological characteristics. This great heterogeneity leads to important disparities in its surgical management as well as in indications for adjuvant therapies. A consensus conference incl...
Source: Bulletin du Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Ballester M, Bendifallah S, Daraï E Tags: Bull Cancer Source Type: research

[Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
lon J Abstract Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic haematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Ther...
Source: Bulletin du Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J Tags: Bull Cancer Source Type: research

[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Abstract In September 2016 in Lille, France, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th Allogeneic Stem Cell Transplantation Clinical Practices Harmonization Workshop Series. Our work group focused on chemotherapy drug dose adaptation for hematopoietic stem cell transplantation patients presenting a comorbidity. The purpose of this workshop was to provide recommendations on chemotherapy drug dose adaptation for patient populations receiving hematopoietic stem cell transplantation who also had the following comorbidities: obesity, chronic kidney disease a...
Source: Bulletin du Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y Tags: Bull Cancer Source Type: research

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
lon J Abstract Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly in the case of after autologous stem cell transplantation if remission can be achieved. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Tr...
Source: Bulletin du Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J Tags: Bull Cancer Source Type: research

[Mechanisms of resistance of cancer stem cells to chemotherapy].
PMID: 29173972 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Pascussi JM Tags: Bull Cancer Source Type: research

[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
lon J Abstract Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellul...
Source: Bulletin du Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J Tags: Bull Cancer Source Type: research

[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Abstract The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2017 in Lille, France and updated recommendations for indications and follow-up in autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases, previously published under the auspices of SFGM-TC. PMID: 29173974 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Pugnet G, Castilla-Llorente C, Puyade M, Terriou L, Badoglio M, Deligny C, Guillaume-Jugnot P, Labeyrie C, Benzidia I, Faivre H, Lansiaux P, Marjanovic Z, Bourhis JH, Faucher C, Furst S, Huynh A, Martin T, Vermersch P, Yakoub-Agha I, Farge D Tags: Bull Cancer Source Type: research

[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
non C Abstract The evolution of HLA typing and transplantation techniques makes it easier to identify a donor for hematopoietic stem cell (HSC) transplantation. This activity, strongly regulated by regulatory or normative texts, implies in addition biological, medical, para-medical and sometimes psychological evaluations. The benefit/risk discussion is complicated because it must take into account the benefit/risk ratio for the recipient, and the donor risk. No Evidence-Based Medicine data is available and serious events are very rare situations. Biovigilance declarations and their analysis are of fundamental impo...
Source: Bulletin du Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Boiron JM, Garban F, Audat F, Ader V, Andreu H, Aubrège-Bouvier C, Borel C, Huynh P, Nacimento F, Yakoub-Agha I, Chabannon C Tags: Bull Cancer Source Type: research

[Cancer stem cells: The true revolution, at last?]
PMID: 29169648 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Robert J Tags: Bull Cancer Source Type: research

[Cancer stem cells: Definition and isolation techniques].
PMID: 29169649 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Ginestier C Tags: Bull Cancer Source Type: research

[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
lon J Abstract Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation (allo-HCT) is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allo-HCT for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed...
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J Tags: Bull Cancer Source Type: research

[Preservation/congelation of hematopoietic stem cell grafts in a pediatric context: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
The objective of our workshop is to provide a discussion on the conservation and congelation of hematopoietic stem cells in a pediatric setting as well as our recommendations for this technique. PMID: 29169651 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: De Vos J, de Berranger E, Jubert C, Pochon C, Letellier C, Mialou V, Sirvent A, Yakoub-Agha I, Dalle JH Tags: Bull Cancer Source Type: research

[The experience of a biotechnology company for preclinical studies of drugs targeting cancer stem cells].
PMID: 29169652 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Cairo S, Judde JG Tags: Bull Cancer Source Type: research

[How I manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus  6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)].
[How I manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)]. Bull Cancer. 2017 Nov 20;: Authors: Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S Abstract The French society of bone marrow transplantation and cell therapy (SFGM-TC) organizes annually workshops in the attempt to harmonize clinical practices between different francophone transplantation center. Here, we report our recommendations regarding the management of Epstein Barr virus react...
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S Tags: Bull Cancer Source Type: research

[The concept of cancer stem cell].
PMID: 29169654 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Charafe-Jauffret E Tags: Bull Cancer Source Type: research

[Cancer stem cells and precision medicine].
PMID: 29169655 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Charafe-Jauffret E Tags: Bull Cancer Source Type: research

[Cancer stem cells and chemotherapy].
PMID: 29162224 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 18, 2017 Category: Cancer & Oncology Authors: Gligorov J, Benderra MA, Zaoui M, Sabbah M, Larsen A Tags: Bull Cancer Source Type: research

[Animal models for the study of cancer stem cells].
PMID: 29157554 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 17, 2017 Category: Cancer & Oncology Authors: Guasch G Tags: Bull Cancer Source Type: research

[Systemic therapy for advanced endometrial cancer].
Abstract Endometrial cancer has generally a good prognosis when diagnosed at an early stage, but remains incurable at an advanced stage (recurrent or metastatic) with only few therapeutic options. Hormonal therapy is the treatment of choice in case of slow progressive disease with a tumor expressing hormonal receptors due to its favorable safety profile. Taxanes, anthracyclines and platinum compounds are the most active chemotherapy agents with greater response rates when combined, though at the price of a significant toxicity. Targeted therapies based on a better understanding of tumor biology are being evaluated...
Source: Bulletin du Cancer - November 17, 2017 Category: Cancer & Oncology Authors: Pautier P, Pommeret F Tags: Bull Cancer Source Type: research

[Epithelial-to-mesenchymal transition and cancer-initiating cells].
PMID: 29157556 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 17, 2017 Category: Cancer & Oncology Authors: Ouzounova M, Puisieux A Tags: Bull Cancer Source Type: research

[Cancer stem cells in colon cancer].
PMID: 29153380 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 16, 2017 Category: Cancer & Oncology Authors: Pannequin J Tags: Bull Cancer Source Type: research

[Aspirin and colorectal cancer].
Abstract Colorectal cancer is a worldwide public health problem. Aspirin has been identified as a protective factor against the apparition of colorectal cancer. There are several mechanisms about the actions by aspirin on colorectal tumorogenesis. These are not perfectly known nowadays. On one hand, there are direct mechanisms on colorectal mucosa, on the other hand there are indirect mechanisms through platelet functions. Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity. Several studies show that long-term treatment with low-doses of aspirin decreases the inciden...
Source: Bulletin du Cancer - November 15, 2017 Category: Cancer & Oncology Authors: Grancher A, Michel P, Di Fiore F, Sefrioui D Tags: Bull Cancer Source Type: research

[Cancer stem cells and metastatic dissemination].
PMID: 29153544 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 15, 2017 Category: Cancer & Oncology Authors: Pannequin J Tags: Bull Cancer Source Type: research

[Cancer stem cells in glioblastoma].
PMID: 29153545 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 15, 2017 Category: Cancer & Oncology Authors: Virolle T Tags: Bull Cancer Source Type: research

[Geriatric assessment and prognostic scores in older cancer patient: Additional support to the therapeutic decision?]
This article presents the set of tools and scores used in geriatric oncology to guide the therapeutic decision. PMID: 29150094 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 14, 2017 Category: Cancer & Oncology Authors: Pamoukdjian F, Liuu E, Caillet P, Gisselbrecht M, Herbaud S, Boudou-Rouquette P, Zelek L, Paillaud E Tags: Bull Cancer Source Type: research

[Towards a better use of midazolam in end of life: A survey in a department of medical oncology].
CONCLUSION: Although limited justifications in midazolam prescriptions could have resulted in an overestimate of sedation and in an underestimate of titrations, current guideline are not enough applied in routine, especially regarding the necessity of a pluridisciplinary decision-making. A list of requirements before midazolam initiation is suggested, to increase the adherence to guidelines. Our results highlight the necessity of a better midazolam use in life-end sedations. PMID: 29150095 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 14, 2017 Category: Cancer & Oncology Authors: Beneton A, Vallard A, Brosse C, Poenou G, Pacaut C, Magné N, Morisson S Tags: Bull Cancer Source Type: research

[Focus on DNA-repair].
PMID: 29132680 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 10, 2017 Category: Cancer & Oncology Authors: Massard C Tags: Bull Cancer Source Type: research

[DNA repair as a therapeutic target].
Abstract The transmission of an intact and stable genetic code at each cell division relies on different DNA repair systems. Germline mutations of some of these genes cause cancer predisposition, whereas somatic mutations are frequently found in various cancer types, generating genomic instability. As a consequence, cancer cell becomes more susceptible to additional DNA damage. Pharmacological inhibition of DNA repair pathways exploits this frailty: it triggers more damages than cancer cell can tolerate, finally leading to apoptosis. The success of PARP (poly-ADP-ribose polymerase) inhibitors in BRCA1/2-mutated ov...
Source: Bulletin du Cancer - November 10, 2017 Category: Cancer & Oncology Authors: Eberst L, Brahmi M, Cassier PA Tags: Bull Cancer Source Type: research

[Biomarkers of radiation-induced DNA repair processes].
te; N Abstract The identification of DNA repair biomarkers is of paramount importance. Indeed, it is the first step in the process of modulating radiosensitivity and radioresistance. Unlike tools of detection and measurement of DNA damage, DNA repair biomarkers highlight the variations of DNA damage responses, depending on the dose and the dose rate. The aim of the present review is to describe the main biomarkers of radiation-induced DNA repair. We will focus on double strand breaks (DSB), because of their major role in radiation-induced cell death. The most important DNA repair biomarkers are DNA damage signalin...
Source: Bulletin du Cancer - November 10, 2017 Category: Cancer & Oncology Authors: Vallard A, Rancoule C, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N Tags: Bull Cancer Source Type: research

[Impairment of DNA damage response and cancer].
te; N Abstract Maintaining the genetic integrity is a key process in cell viability and is enabled by a wide network of repair pathways. When this system is defective, it generates genomic instability and results in an accumulation of chromosomal aberrations and mutations that may be responsible for various clinical phenotypes, including susceptibility to develop cancer. Indeed, these defects can promote not only the initiation of cancer, but also allow the tumor cells to rapidly acquire mutations during their evolution. Several genes are involved in these damage repair systems and particular polymorphisms are pre...
Source: Bulletin du Cancer - November 10, 2017 Category: Cancer & Oncology Authors: Rancoule C, Vallard A, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N Tags: Bull Cancer Source Type: research

[Crossed perceptions about malnutrition in patients and their doctors in oncology].
t Guily J, Gyan E Abstract Malnutrition is common in oncology. However, it is often detected too late and nutritional support is sub-optimal. The patient's opinion, although often sought in therapeutic decisions in oncology, does not appear to be frequently taken into account in dietetic management. In NutriCancer2012 study, we interviewed patients, relatives and doctors about their perceptions of the impact of malnutrition and its quality of care. Of the 2209 patients questioned, majority said they were concerned about nutrition with 75% considering it essential to take appropriate nutritional care but only ...
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Raynard B, Hébuterne X, Goldwasser F, Ait Hssain A, Dubray Longeras P, Barthélémy P, Rosso E, Phoutthasang V, Bories C, Digue L, Laharie D, Desport JC, Falkowski S, Lacau Saint Guily J, Gyan E Tags: Bull Cancer Source Type: research

[Why and how to promote decision-making autonomy of cancer patients?]
Abstract Involvement of patients in decision-making about their health has been promoted nationally and internationally since several years. Despite this, patient (and their relatives) participation remains insufficient and one of the objectives of the current French national cancer policy (Plan cancer 2014-2019) is to give everyone the possibility to play an active role in the management of their care. This overview focuses on decision-making autonomy of cancer patients through two main questions: why and how to promote it? After a brief review of the decision-making models described in the literature in the past...
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Mancini J Tags: Bull Cancer Source Type: research

[National care logbook for patients undergoing autologous hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
gha I Abstract In an attempt to harmonize clinical practices among French hematopoietic stem cell transplantation centers, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held its seventh annual workshop series in September 2016 in Lille. This event brought together practitioners from across the country. Our workshop discusses the creation of a patient care logbook for patients undergoing autologous hematopoietic cell transplantation. PMID: 29128082 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Porcheron S, Balcaen S, Cardinael N, Courbon C, Dendoncker C, Faivre-Lescat H, François G, Gilis L, Guiraud M, Schmitt S, Vercasson M, Adam C, Yakoub-Agha I Tags: Bull Cancer Source Type: research

Evolution of hepatocellular carcinoma epidemiology in C ôte d'Ivoire.
DISCUSSION: Ivorian epidemiology of hepatocellular carcinoma was reshaped during the last decades. These changes, most likely due to the spread of hepatitis C virus, resulted in an older and feminized population of patients. We fear that the current and future prevalence of anti-HCV cases might thwart the expected benefits of anti-hepatitis B immunization. Appropriate measures should be taken to prevent further transmission of hepatitis C in the country. PMID: 29128083 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Didi-Kouko Coulibaly J, Yeboua M, Kouassi Mbengue A, Kouadio EA, Anzouan-Kacou Kissi H, Binan AY, Lohoues Kouacou MJ, Attia A, N'Drin DY, Toutou T, Adoubi I, Pineau P Tags: Bull Cancer Source Type: research

[Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Abstract Chimerism analysis is an important step for the patient follow-up after hematopoietic stem cell transplantation. It is used to quantify the donor and the recipient part of a cell population issued from blood or bone marrow sample. In addition to hemogram, this technique is necessary to appreciate the quality of engraftment. The aim of this article is to propose some recommendation about methods, result analysis and therapeutic decision in hematopoietic stem cell transplantation for malignant or non-malignant diseases. PMID: 29128084 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Dubois V, Alizadeh M, Bourhis JH, Etancelin P, Farchi O, Ferrand C, Goursaud L, Mollet I, Renac V, Varlet P, Yakoub-Agha I, Bay JO Tags: Bull Cancer Source Type: research

[HLA coding in ProMISe: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Abstract As part of the 7th Annual francophone workshop series on the harmonization of clinical practices in allogeneic stem cell transplantation held in Lille in September 2016, our workgroup discussed how transplant centers might follow a collective approach to coding data. This was done mainly by analyzing the study results found in the literature that do not provide clear answers. In addition, we discuss practical ways of coding for both donor and recipient HLA typing in the European bone marrow transplantation database called ProMISe which is managed by the European Society for Blood and Marrow Transplantatio...
Source: Bulletin du Cancer - November 8, 2017 Category: Cancer & Oncology Authors: Raus N, Faucher C, Kennel A, Pereira M, Veron C, Yakoub-Agha I, Loiseau P Tags: Bull Cancer Source Type: research

[Information booklet for related hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Abstract Providing information to living donors is first and foremost a legal obligation as well as an ethical one, not to mention necessary to health care provision. It's been shown that quality of information concerning the procedure's practical aspects, scheduling of clinical tests and examinations, withdrawing stem cells for the donation, post-donation symptoms, and support provided by healthcare teams, directly impacts the donor's quality of experience. Taking this into consideration our group decided it was essential to create an informational support for donors in the form of a booklet to be provided in dif...
Source: Bulletin du Cancer - November 7, 2017 Category: Cancer & Oncology Authors: Polomeni A, Tardieu L, Ainaoui M, Andrianne C, Bancillon N, Chapel V, Chevallier N, Evrard S, Fournier I, Gargallo G, Godin S, Issarni D, Le Bars L, Renaud B, Yakoub-Agha I, Wallart A, De Bentzmann N Tags: Bull Cancer Source Type: research

[Analysis of uterus cervical cancer screening campaign results in Conakry, Guinea].
CONCLUSION: Our research shows that, with creativity, flexibility, good organization and efficient use of resources, morbidity and death rates of women with cervical cancer in a very resources can be significantly reduced. PMID: 29126586 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 7, 2017 Category: Cancer & Oncology Authors: Leno DWA, Diallo FD, Camara AY, Magassouba M, Komano FD, Traore A, Niamy D, Tolno J, Cissoko O, Bangoura M, Keita N Tags: Bull Cancer Source Type: research

[Marie Curie and medicine].
PMID: 29117905 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 5, 2017 Category: Cancer & Oncology Authors: Dutreix M Tags: Bull Cancer Source Type: research

Marie Curie.
PMID: 29113680 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 4, 2017 Category: Cancer & Oncology Authors: Dutreix M Tags: Bull Cancer Source Type: research

[The 150th anniversary of Marie Curie].
iat J PMID: 29108642 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - November 3, 2017 Category: Cancer & Oncology Authors: Mazeron JJ, Magné N, Thariat J Tags: Bull Cancer Source Type: research

[Clinical trials and perspectives of radiotherapy for uterine endometrial cancers].
Abstract The adjuvant management of uterine endometrial cancer has been studied in many randomized trials, leading to define postoperative therapeutic indications, depending on the risk factors for relapse, and on the expected benefit in terms of locoregional control and survival. The potential toxicity of treatments should be also considered. We review the available literature that yielded to guidelines that were recently published, on behalf of European societies, and we highlight the perspectives on ongoing studies, aimed at better defining the place and type of adjuvant treatment. PMID: 29100604 [PubMed -...
Source: Bulletin du Cancer - October 31, 2017 Category: Cancer & Oncology Authors: Chargari C, Maroun P, Lazarescu I, Haie-Meder C Tags: Bull Cancer Source Type: research

[HBV infection: Screening and treatment for oncology patients].
This article proposes an overview on screening strategies and antiviral treatment recommendations for oncology patients. We have learned in hematology that reactivations are commun with rituximab and prophylactic treatment is recommanded for any patient who has been in contact with the virus. The risk appears to be lower with cytotoxics but has been far less studied. The recommandations are not formally consensual and upcoming studies will help to establish clearer practice guidelines. PMID: 29066086 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 21, 2017 Category: Cancer & Oncology Authors: Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S Tags: Bull Cancer Source Type: research

[Lynch syndrome and endometrial cancer].
Abstract Lynch syndrome is a hereditary predisposition to many tumors, in the forefront of which endometrial cancer in women. It is related to the mutation of a mismatch repair gene, involved in DNA mismatch repair. This mutation leads to a loss of expression of the corresponding protein, and to genome instability in tumor cells. Cumulative risk at the age of 70 years is over 40 %. Endometrial cancers related to Lynch syndrome are most of the time sentinel (They reveal the predisposition in half of families.) and are characterized by young age at onset (before 60 years) and low body mass index compared with p...
Source: Bulletin du Cancer - October 21, 2017 Category: Cancer & Oncology Authors: Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F Tags: Bull Cancer Source Type: research

[Abnormalities of DNA repair and gynecological cancers].
Abstract The demonstration of frequent defects in the DNA damage response in high grade ovarian cancer has paved the way for a new therapeutic approach aimed at exploiting this unique vulnerability. The efficacy of poly (ADP) ribose polymerase inhibitors (PARPi) in patients with homologous recombination (HR) DNA repair deficient ovarian cancer (OC) resulting from a BRCA1/2 mutation has provided the proof of concept for synthetic lethality. Thus, olaparib is now approved by the EMA as maintenance therapy after response to a platinum regimen for patients with recurrent, platinum-sensitive, high-grade serous, BRCA1/2...
Source: Bulletin du Cancer - October 17, 2017 Category: Cancer & Oncology Authors: Auguste A, Leary A Tags: Bull Cancer Source Type: research

[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy].
Abstract New routes of administration available for some targeted therapies, especially subcutaneous injections, have an impact not only on the patients' daycare experience, but also on the unit's organization. This observational study conducted on 48 voluntary patients at the Institut universitaire du cancer Toulouse-Oncopole shows that the mean duration of the outpatient unit stay is diminished by one hour when a subcutaneous injection is used instead of an intravenous route. This duration decrease is mainly caused by an 82% average reduction in treatment duration. However, the waiting times before and after the...
Source: Bulletin du Cancer - October 12, 2017 Category: Cancer & Oncology Authors: Despiau F, Zagala Y, Delord JP, Montastruc M, Lacaze JL, Ferrand R, Bombail M Tags: Bull Cancer Source Type: research